Timothy Waterhouse - Concepedia

Author

Timothy Waterhouse

Eli Lilly (United States)ORCID

Also Known As

, T Waterhouse, T. H. Waterhouse, T.H. Waterhouse, Tim Waterhouse, Timothy H. Waterhouse, Timothy Waterhouse

Publications

356

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)The University of Queensland

About

Timothy Waterhouse is an author at Eli Lilly (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	102
2	Biostatistics	3	3	77
3	Public Health	1	1	22
4	Endocrinology	1	1	22
5	Nephrology	1	1	13

Timothy Waterhouse

Publications

299

Citations

H-Index

Page 1

	Year	Citations
Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug Md L T Vieira, Brian J. Kirby, Isabelle Ragueneau‐Majlessi, Clinical Pharmacology & Therapeutics	2013	101
A<scp>d</scp>‐optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients Stefanie Hennig, Timothy Waterhouse, Scott C. Bell, British Journal of Clinical Pharmacology	2006	47
Optimal Design for Model Discrimination and Parameter Estimation for Itraconazole Population Pharmacokinetics in Cystic Fibrosis Patients Timothy Waterhouse, S. Redmann, Stephen B. Duffull, Journal of Pharmacokinetics and Pharmacodynamics Pharmacokinetic ModelingModel DiscriminationMedicineCystic Fibrosis PatientsOptimal Design	2005	40
Design selection criteria for discrimination/estimation for nested models and a binomial response Timothy Waterhouse, David C. Woods, J. A. Eccleston, Journal of Statistical Planning and Inference Design Selection CriteriaChoice ModelSelection BiasNested ModelsBinomial Response	2007	27
Optimal Design Criteria for Discrimination and Estimation in Nonlinear Models Timothy Waterhouse, J. A. Eccleston, Stephen B. Duffull Journal of Biopharmaceutical Statistics	2009	22
Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients Venkatesh Krishnan, Nita Patel, James G. MacKrell, Andrology Hormonal ContraceptiveFertilitySkin Absorption PropertiesReproductive HealthGynecology	2018	22
The Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Evacetrapib Administered as Monotherapy or in Combination With Statins S Friedrich, JJP Kastelein, Douglas E. James, CPT Pharmacometrics & Systems Pharmacology Evacetrapib PharmacokineticsEvacetrapib AdministeredEvacetrapib ExposurePharmacodynamicsCardiovascular Disease	2014	17
Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease Evan B. Wang, Archana Chaudhary, Timothy Waterhouse, The Journal of Clinical Pharmacology HypertensionOral BioavailabilityRenal FunctionHealthy SubjectsCardiovascular Disease	2017	13
Optimal Crossover Designs for Logistic Regression Models in Pharmacodynamics Timothy Waterhouse, J. A. Eccleston, Stephen B. Duffull Journal of Biopharmaceutical Statistics Drug DesignBinary ResponsePharmacologyOptimal DesignsMultiple Periods	2006	10

Page 1